274 related articles for article (PubMed ID: 15637399)
1. Prevention of hormone-related cancers: prostate cancer.
Parnes HL; Thompson IM; Ford LG
J Clin Oncol; 2005 Jan; 23(2):368-77. PubMed ID: 15637399
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer prevention and finasteride.
D'Amico AV; Barry MJ
J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
[TBL] [Abstract][Full Text] [Related]
3. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
Platz EA; Giovannucci E
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
[TBL] [Abstract][Full Text] [Related]
4. High-grade prostate cancer and finasteride.
Lebdai S; Bigot P; Azzouzi AR
BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
[TBL] [Abstract][Full Text] [Related]
5. Androgens and the molecular epidemiology of prostate cancer.
Chu LW; Reichardt JK; Hsing AW
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):261-70. PubMed ID: 18438175
[TBL] [Abstract][Full Text] [Related]
6. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
Mellon JK
Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
[TBL] [Abstract][Full Text] [Related]
7. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
Goetzl MA; Holzbeierlein JM
Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
[TBL] [Abstract][Full Text] [Related]
8. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
9. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological approaches to reducing the risk of prostate cancer.
Rittmaster RS; Fleshner NE; Thompson IM
Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice.
Canby-Hagino ED; Thompson IM
Nat Clin Pract Oncol; 2005 May; 2(5):255-61. PubMed ID: 16264961
[TBL] [Abstract][Full Text] [Related]
13. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.
Canby-Hagino E; Hernandez J; Brand TC; Thompson I
Eur Urol; 2007 Jan; 51(1):27-33. PubMed ID: 17030406
[TBL] [Abstract][Full Text] [Related]
14. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
15. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
16. Update on chemoprevention for prostate cancer.
Strope SA; Andriole GL
Curr Opin Urol; 2010 May; 20(3):194-7. PubMed ID: 20216317
[TBL] [Abstract][Full Text] [Related]
17. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer prevention: risk reduction through life-style, diet, and chemoprevention.
Greco KE; Kulawiak L
Oncol Nurs Forum; 1994 Oct; 21(9):1504-11. PubMed ID: 7816677
[TBL] [Abstract][Full Text] [Related]
19. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
20. Effect of finasteride on risk of prostate cancer: how little we really know.
Rubin MA; Kantoff PW
J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]